Harvard Economist: Flu Vaccine Shortage Could Cost Businesses $20B

This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.

The New York Sun

WASHINGTON – This year’s flu vaccine shortage could cost the nation up to $20 billion in lost productivity – almost twice as much as in a typical year – depending on the severity of the outbreak, according to one estimate.


The average worker misses about 1 to 1.5 days a year because of the flu, said David Cutler, a health economist at Harvard. That absenteeism rate could double because of scant flu vaccine supplies this year.


“There’s an enormous margin of error: how bad the flu will be,” Mr. Cutler said of his estimate. “That’s where the real uncertainty is.”


One vaccine expert says early indications – and milder flu outbreaks in Australia and New Zealand – suggest this flu season in America could be mild. The most recent statistics from the CDC indicate low flu activity in seven states.


“It’s not ‘We’re getting ready to close the school down, there are so many cases,'” Dr. Greg Poland said of the sporadic reports. Dr. Poland is director of the Mayo Clinic’s vaccine research group and one of the government’s vaccine experts.


The dominant virus strain, so far, is contained in this year’s vaccine and sickened up to 30% of Americans last year, providing some carry-over immunity.Dr. Poland cautioned that the nation is just beginning the flu season, which most often peaks in January or later.


Federal authorities learned in early October that Chiron Corp. would be unable to supply 46 million to 48 million flu vaccine doses, due to British regulatory action. The FDA, which sent inspectors in early October, agreed Chiron’s flu vaccine was not safe to use.


The Centers for Disease Control and Prevention is working with Aventis Pasteur to ensure the next wave of flu vaccine – 24 million shots – reaches those at the highest risk.


The number of high-risk individuals seeking shots exceeds the 58 million flu doses Aventis expects to provide this year. It’s unclear how many healthy Americans will receive flu shots.


Employers typically purchase 10 million to 20 million flu shots to sponsor flu clinics at work. Sixty percent of companies responding to a Society for Human Resource Management survey in June said they would hold flu clinics this year. Many of those workplace flu clinics were shelved to funnel vaccine to high-risk individuals, including the very young, the very old, and those with chronic medical conditions.


This year’s flu vaccine shortage could cause deaths to spike by 25%, said Dr. John Treanor, an infectious disease expert at the University of Rochester Medical Center. In a typical year,36,000 Americans die from the flu. That mortality figure rises to 51,000 when flu-related complications, like heart attacks and strokes, are included.


Health and Human Services Secretary Thompson on Tuesday again urged seniors to get vaccinated to protect against pneumonia, another flu complication.


Merck & Company, the sole supplier of that vaccine, yesterday said it would make an additional 11 million doses of Pneumovax 23. That raises this year’s production to 17 million doses. In a typical year, the company sells 6 million to 7 million doses of the pneumococcal vaccine.


Vaccinating healthy Americans against the flu, some studies indicate, is cost-effective, saving at least $13.66 per person.


ComPsych Corp. this year canceled its annual workplace flu shot programs covering thousands of employees. In past years, the employee assistance program found that flu shots dramatically reduced worker absenteeism.


Only 7% of employees vaccinated for the flu missed work due to that illness. That compares with 40% who missed work for their own flu sickness when they weren’t vaccinated, ComPsych found.


Parents of children vaccinated with FluMist missed 72% fewer days of work, a University of Maryland School of Medicine study showed.


The study will be repeated in Maryland, Minnesota, Texas, and Washington state this year.


The results were “almost too good, that’s why we’re repeating it,” said James C. King, a pediatrics professor who tests vaccines.


The New York Sun

© 2025 The New York Sun Company, LLC. All rights reserved.

Use of this site constitutes acceptance of our Terms of Use and Privacy Policy. The material on this site is protected by copyright law and may not be reproduced, distributed, transmitted, cached or otherwise used.

The New York Sun

Sign in or  Create a free account

or
By continuing you agree to our Privacy Policy and Terms of Use